Aurealis Pharma raised €6.9M in a Series B round in Jan 2019. The company is based in Kuopio, Finland. Investors in the round: Finnvera Venture Capital. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
This is the company's only recorded round.